Journal
EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY
Volume 15, Issue 6, Pages 546-554Publisher
AMER PSYCHOLOGICAL ASSOC
DOI: 10.1037/1064-1297.15.6.546
Keywords
Alzheimer's disease; acetylcholinesterase inhibitors; attention; subtypes
Ask authors/readers for more resources
Cholinergic neurons are extensively implicated in cognitive functioning. Cholinergic deficiency is a widely accepted hypothesis of cognitive decline in Alzheimer's disease (AD) and is the impetus for the development of cholinesterase inhibitors (ChIs). Studies on the efficacy of ChIs emphasize global cognitive improvement and the amelioration of neuropsychiatric symptoms associated with AD. The authors propose that the current perception of ChIs as global cognitive enhancers may be misleading. It is hypothesized that these drugs improve cognition in specific AD subtypes primarily through psychotropic properties that facilitate attentional processing. In effect, increased attentional capacity through diminished neuropsychiatric symptoms serves to augment results on global cognitive measures: in particular, AD subtypes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available